Today we talk about why India’s medical tourism industry is imploding despite official growth numbers showing the opposite.
Quick disclaimer before we begin. Stocks or sectors mentioned here are only for context and not investment advice. Please do your own research or consult a registered financial advisor before investing.
Now onto today’s story.
The Story
Here’s a puzzle that should worry you.
In 2024, India welcomed 6.44 lakh foreign patients coming specifically for medical treatment. That number jumped from 4.3 lakh in 2016. Growth. Upward trajectory. Happy headlines.
Market analysts are calling it a boom. The India medical tourism market is valued at USD 20.4 billion in 2026, supported by rising international patient inflows and strong private hospital capacity, and is forecasted to expand at a 12.3% CAGR from 2026 to 2036, reaching USD 65.1 billion by 2036. Government ministers are tweeting about it. Hospital chains are expanding capacity. Private equity is betting billions.
But walk into a hospital in Kolkata right now. The quietness will tell you a different story.
So what’s actually happening?
Let’s talk about Bangladesh first. For decades, it was India’s golden goose. Bangladesh accounts for nearly 70% of India’s medical tourism. Patients from Dhaka would cross the border to Kolkata. Patients from smaller towns would travel to Delhi or Hyderabad. It was a steady, predictable river of cash flowing into Indian hospitals.
Then August 2024 happened. Political upheaval in Dhaka. Sheikh Hasina fled to India. Tensions exploded. India tightened its visa operations for Bangladeshi citizens. Bangladesh reciprocated.
The effect? A 73% drop in tourist arrivals from Bangladesh. Not a dip. A freefall. Hospitals that had built entire units around Bangladeshi patients suddenly had empty beds. Since late August, the number of Bangladeshi patients has dropped by 80 percent. One hospital director told us the waiting time for visa approvals went from days to weeks. For patients needing urgent transplants, that’s not a bureaucratic inconvenience. That’s a death sentence.
Apollo Hospitals, Medanta, Narayana Health—the big chains that advertise internationally—suddenly had to announce lower patient inflows in their quarterly earnings. But the real damage was to smaller hospitals in East India that depend almost entirely on Bangladeshi patients.
But wait. If Bangladesh alone accounts for 70%, shouldn’t the overall numbers have collapsed?
They should have. They haven’t. Why?
Because there’s a second story unfolding at the same time. The numbers are being propped up by lower-value procedures. More cosmetic surgeries. More dental work. More routine treatments that come with smaller margins and shorter hospital stays. The mix of what “medical tourism” means has fundamentally shifted.
As of March 2026, major hospital chains, including Fortis Healthcare and Artemis Medicare Services, have noted a sharp decline in footfall from countries such as Oman, Iraq, and Yemen. This downturn is primarily attributed to airspace closures, surging travel costs, and a general climate of regional instability that has deferred elective and non-urgent medical procedures.
The Gulf was the second pillar. Not in volume, but in value. Patients from the Gulf typically opt for premium accommodations and undergo complex, high-margin procedures such as organ transplants and advanced cancer treatments. One liver transplant from a Gulf patient generates more revenue than fifty cosmetic surgeries. But Iran’s war has closed airspace. It’s made flights expensive. It’s made travel risky.
So now hospitals are chasing low-margin business. Cost per patient is down. Complexity is down. Revenue per bed is down.
The official numbers look okay because you’re measuring passengers on a bus, not the price of the ticket.
Here’s where the real problem sits.
India’s medical tourism success was built on a mirage of stability. It was never truly diversified. It leaned heavily on two regions: Bangladesh (proximity, language, culture) and the Gulf (purchasing power, complex cases, referral networks). Together, they were the backbone.
But India kept talking as if the market was global. International marketing. Glossy websites. The “Heal in India” initiative. Government ministers announcing growth rates. Everyone pretended it was a geographically balanced market. It wasn’t.
The moment geopolitics shifted, the whole structure wobbled. Regulatory Barriers: Cumbersome visa processes and fragmented regulatory frameworks across states hinder patient inflow and hospital coordination. Safety Concerns: Issues related to personal safety, particularly for women and foreign tourists, pose reputational risks to the sector.
And the government response? Delayed. India has proposed a new visa-on-arrival policy for US and European medical travellers to make medical and wellness tourism easier, faster, and more accessible. Note the word “proposed.” This was announced in November 2025. In March 2026, it still hasn’t been implemented. Meanwhile, hospitals are burning cash.
But there’s a third knife in the back that nobody’s discussing.
The biggest competitor to India isn’t Thailand anymore. It’s not Mexico. It’s geopolitical fragility. It’s visa uncertainty. It’s infrastructure that looks good in brochures but falls apart in reality.
Visitors may encounter overflowing dhalaos filled with decaying medical and general waste, puddle-riddled roads that serve as breeding grounds for mosquitoes, unkempt toilets, and corridors transformed into makeshift dhobis with clothes hung out to dry.
That’s not from some random hospital. That’s from reports on major Indian medical centers. A patient flying across borders for a kidney transplant doesn’t want to see soiled laundry in hospital corridors. They don’t want to risk a post-operative infection from poor sanitation. Thailand’s Bumrungrad Hospital doesn’t have these problems. Turkey’s hospitals are cleaner. Mexico’s private chains are better organized.
India keeps marketing itself as a cost-effective destination. But cost-effectiveness only works if the alternative is unaffordable. What happens when the alternative becomes safer, cleaner, and only slightly more expensive?
You lose patients.
Limited number of accredited hospitals contributes to a lack of trust among tourists regarding Indian healthcare facilities. India has thousands of hospitals. But how many are actually accredited by international bodies like JCI or NABH? The number is far smaller than it should be. So patients either come to one of the few trusted chains (and those hospitals are overloaded) or they take their business elsewhere.
The government knows this. The Union Budget 2026-27 has recently proposed the establishment of five “Regional Medical Hubs” to bolster the nation’s infrastructure. These hubs are intended to provide integrated care complexes that combine allopathic treatments with AYUSH centres, creating a unique value proposition for the “wellness” traveller.
Again, “proposed.” Infrastructure takes years. Patients need care now.
So what do the numbers actually tell us?
They tell us that India is chasing volume to hide a collapse in value. The total foreign tourist arrivals for medical purposes are still in the 6+ lakh range. Looks healthy. But dig deeper and during the January–November period of 2025, more than 4.5 lakh foreign tourists visited India for medical purposes, according to provisional figures. That’s lower than 2024. Trend is down. And these numbers include everything from consultations to full surgeries.
The money per patient is falling. The geographic concentration is terrifying. And the competitive advantage—cost—is eroding because traveling to India is no longer cheap. Flights are expensive. Visa procedures eat time (and money). Hotels near hospitals charge premium rates because they know international patients are desperate.
But here’s the darkest irony. India medical tourism market beneficiaries pay 60-80% less than OECD rates, with bypass grafts starting at USD 5,000 against USD 100,000 in the United States. Lower labor costs, high generic-drug penetration, and dense patient throughput sustain the edge. The cost advantage is real. But cost advantage only matters if people can actually access it. And if your visa system is broken, your hospital is overcrowded, and the region you operate in is geopolitically unstable, cost doesn’t matter anymore.
A patient in Oman doesn’t care if a heart surgery costs USD 15,000 in India if they can’t get a visa on time. They’ll fly to Turkey and pay USD 25,000 instead.
Until then…
If this piece helped clarify the cracks in India’s medical tourism narrative, do share it with someone investing in healthcare stocks or considering the sector for expansion.
This article is for educational purposes only. Not investment advice.
Happy Investing 😎
Nataraj Malavade
Investor, Trader, Author & Mentor
blog.natarajmalavade.in
| # |
Publication |
Article |
Link |
| 1 |
Al Jazeera |
Medical victims: Indian visa curbs amid Bangladesh tensions hurt patients |
Read |
| 2 |
Business Today |
India’s medical tourism takes a hit as patient arrivals from Bangladesh plunge amid visa restrictions |
Read |
| 3 |
DD News |
Over 6.4 lakh foreign tourists visited India for medical treatment in 2024 |
Read |
| 4 |
Travel and Tour World |
India’s Medical Tourism Pivot 2026: Why the Iran Conflict Is Forcing Hospitals Into New Global Markets |
Read |
| 5 |
Future Market Insights |
India Medical Tourism Market (2026 - 2036) |
Read |
| 6 |
IMPRI |
Challenges In Enhancing India As A Global And Regional Medical Tourism |
Read |
| 7 |
IMPRI |
India’s Medical Tourism: Strengthening a Global Healthcare Destination through Governance and Policy Reform |
Read |
| 8 |
Toward Healthcare |
India’s New Visa-on-Arrival Policy to Boost Global Medical Tourism |
Read |
| 9 |
Mordor Intelligence |
India Medical Tourism Market Size, Share, Trends |
Read |
| 10 |
Travel and Tour World |
India’s Medical Tourism Growth Set to Surge with Pre-Budget Signals |
Read |
